tiprankstipranks
Advertisement
Advertisement
Voyager Therapeutics: Undervalued Neurology Pipeline With High-Reward 2026 Catalysts Supports Buy Rating
PremiumRatingsVoyager Therapeutics: Undervalued Neurology Pipeline With High-Reward 2026 Catalysts Supports Buy Rating
1M ago
Voyager Therapeutics: 2026 Tau Data Catalysts and Gene Therapy Milestones Support Buy/High Risk Rating
Premium
Ratings
Voyager Therapeutics: 2026 Tau Data Catalysts and Gene Therapy Milestones Support Buy/High Risk Rating
1M ago
Voyager Therapeutics reports Q4 EPS (46c), consensus (51c)
Premium
The Fly
Voyager Therapeutics reports Q4 EPS (46c), consensus (51c)
1M ago
Voyager Therapeutics Reports Increased Losses Amid Rising R&D Costs
PremiumCompany AnnouncementsVoyager Therapeutics Reports Increased Losses Amid Rising R&D Costs
5M ago
Voyager Therapeutics: Strong Financial Position and Promising Pipeline Justify Buy Rating
Premium
Ratings
Voyager Therapeutics: Strong Financial Position and Promising Pipeline Justify Buy Rating
5M ago
Voyager Therapeutics files $400M mixed securities shelf
Premium
The Fly
Voyager Therapeutics files $400M mixed securities shelf
5M ago
Voyager Therapeutics Advances Alzheimer’s Study with VY7523
PremiumCompany AnnouncementsVoyager Therapeutics Advances Alzheimer’s Study with VY7523
6M ago
Voyager Therapeutics: Strategic Positioning and Regulatory Endorsements Drive Buy Rating
Premium
Ratings
Voyager Therapeutics: Strategic Positioning and Regulatory Endorsements Drive Buy Rating
6M ago
Voyager Therapeutics: Promising Alzheimer’s Portfolio and Innovative NeuroShuttle Platform Justify Buy Rating
Premium
Ratings
Voyager Therapeutics: Promising Alzheimer’s Portfolio and Innovative NeuroShuttle Platform Justify Buy Rating
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100